Filing Flows › Acadia Pharmaceuticals (ACAD) › Capital expenditures
Acadia Pharmaceuticals (ACAD) capital expenditures by quarter
Acadia Pharmaceuticals' capital expenditures were $1.2M in Q3 2026 (third quarter 2026), -76% from Q2 2026. Over the last 5 quarters it ranged from $297K (Q2 2025) to $5.2M (Q1 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.2M | -76% | +220% |
| Q2 2026 | $5.1M | -2% | 17× |
| Q1 2026 | $5.2M | 13× | — |
| Q3 2025 | $388K | +31% | — |
| Q2 2025 | $297K | — | — |
Q3 2026 at a glance
Acadia Pharmaceuticals, Q3 2026: revenue $342M (+23% year over year), operating margin 21.0%, net earnings $53.5M, operating cash flow $11.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Acadia Pharmaceuticals' capital expenditures?
Acadia Pharmaceuticals' capital expenditures were $1.2M in Q3 2026 (third quarter 2026), -76% from Q2 2026.
How has Acadia Pharmaceuticals' capital expenditures changed?
Over the last 5 quarters it ranged from $297K (Q2 2025) to $5.2M (Q1 2026).
Q3 2026 results → · How Acadia Pharmaceuticals makes money →